Definition
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
Description
Dacarbazine is only found in individuals that have used or taken this drug. It is an antineoplastic agent. It has significant activity against melanomas. The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific.
Top Gene Interactions
Related Pathways
Dacarbazine Health Effects
General Information
- Metabolism: Hepatic. Route of Elimination: Dacarbazine is subject to renal tubular secretion rather than glomerular filtration. In man, dacarbazine is extensively degraded. Besides unchanged dacarbazine, 5-aminoimidazole -4 carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine. Half Life: 5 hours
- Uses/Sources: Dacarbazine is used in the treatment of various cancers, among them malignant melanoma, Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas. As of mid-2006, dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma, and as part of the ABVD chemotherapy regimen to treat Hodgkin lymphoma, and in the MAID regimen for sarcoma. (Wikipedia)
- Route of Exposure: Erratic, slow and incomplete.
Toxicity
- Carcinogenicity: 2B, possibly carcinogenic to humans. (L135)
- Toxicity: LD<sub>50</sub>=350mg/kg (orally in mice)
Mechanism of Action
| Target Name | Mechanism of Action | References |
|---|---|---|
|
DNA DNA polymerase alpha subunit B 6-phosphogluconate dehydrogenase, decarboxylating |
17139284 17016423 10592235 20235752 3098406 |
Dacarbazine Interacts with Diseases
| Disease | Inference Score | References/Inference Genes |
| Squamous cell carcinoma | 21.63 | |
| Hepatocellular carcinoma | 21.2 | |
| Lung Neoplasms | 20.66 | |
| Stomach Neoplasms | 19.04 | |
| Radiation Injuries, Experimental | 18.62 |
|
| Brain Injuries | 18.29 | |
| Colorectal cancer | 18.24 | |
| Sepsis | 17.96 | |
| Ovarian Neoplasms | 17.85 | |
| Melanoma | 17.82 | |
| Diabetes Mellitus, Type 2 | 17.17 | |
| Leishmaniasis | 16.4 |
|
| Breast carcinoma | 15.51 | |
| Leukemia-Lymphoma, Adult T-Cell | 15.4 |
|
| Visceral leishmaniasis | 15.34 | |
| Thyroid carcinoma | 14.86 |
|
| Diabetes Mellitus, Experimental | 14.42 | |
| Neoplasm Metastasis | 14.42 | |
| Pneumonia, Pneumococcal | 14.38 |
|
| Arthritis, Experimental | 14.03 |